Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.
Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.
Eli Lilly reported 74% of patients treated with tirzepatide achieved resolution of metabolic dysfunction-associated steatohepatitis, or MASH. However, the Phase 2 results showed only “clinically meaningful” improvement in resolving liver fibrosis, a key measure of the drug's potential competitiveness in a crowded field of contenders.